Experienced in Alveolar Soft Part Sarcoma

Dr. Marilyn S. Huang

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
University Of Virginia Physicians Group
1240 Lee St, 
Charlottesville, VA 
Accepting New Patients
Offers Telehealth
Experienced in Alveolar Soft Part Sarcoma
University Of Virginia Physicians Group
1240 Lee St, 
Charlottesville, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marilyn Huang is a Gynecologic Oncologist and an Oncologist in Charlottesville, Virginia. Dr. Huang is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer, and Hysterectomy. Dr. Huang is currently accepting new patients.

Her clinical research consists of co-authoring 75 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in VA
Hospital Affiliations
University Of Virginia Medical Center
Languages Spoken
English
Mandarin
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNIVERSITY OF VIRGINIA PHYSICIANS GROUP
1240 Lee St, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma
A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma
Enrollment Status: Suspended
Publish Date: July 28, 2025
Intervention Type: Procedure, Drug
Study Drug: Triapine
Study Phase: Early Phase 1
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: SGN-STNV
Study Phase: Phase 1
Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Enrollment Status: Terminated
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab
Study Phase: Phase 2
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2023
Intervention Type: Drug
Study Drugs: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
Study Phase: Phase 3
Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel, Carboplatin
Study Phase: Phase 2
A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 1/Phase 2
Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN)
Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN)
Enrollment Status: Withdrawn
Publish Date: February 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

75 Total Publications

Ivermectin and gynecologic cancer: What's the data?
Ivermectin and gynecologic cancer: What's the data?
Journal: Gynecologic oncology reports
Published: June 08, 2025
Similar Doctors
William W. Grosh
Advanced in Alveolar Soft Part Sarcoma
Dr. William W. Grosh
Hematology Oncology | Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. William W. Grosh
Hematology Oncology | Hematology | Oncology
1240 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-9333
Languages Spoken:
English

William Grosh is a Hematologist Oncology specialist and a Hematologist in Charlottesville, Virginia. Dr. Grosh is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Melanoma, Osteosarcoma, Neuroendocrine Tumor, and Bone Tumor.

Advanced in Alveolar Soft Part Sarcoma
Dr. Radhika M. Thorn
Hematology Oncology | Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Radhika M. Thorn
Hematology Oncology | Hematology | Oncology

Bon Secours-Richmond Community Hospital LLC

14051 St Francis Blvd, Suite 2210, 
Midlothian, VA 
 (60.1 miles away)
804-893-8717
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Radhika Thorn is a Hematologist Oncology specialist and a Hematologist in Midlothian, Virginia. Dr. Thorn is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Hemochromatosis, Small Cell Lung Cancer (SCLC), Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Thorn is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Ludimila L. Cavalcante
Oncology | Hematology Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Ludimila L. Cavalcante
Oncology | Hematology Oncology

University Of Virginia Physicians Group

1240 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-5191
Experience:
16+ years
Languages Spoken:
English, French, Italian, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ludimila Cavalcante is an Oncologist and a Hematologist Oncology provider in Charlottesville, Virginia. Dr. Cavalcante has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Synovial Sarcoma, Alveolar Soft Part Sarcoma, Mesenchymoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Cavalcante is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huang's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 10 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile